January 30, 2019 Bio/Pharma/CRO Clinical Research/Diagn.

Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer’s disease (AD) – other company programmes in AD continue

Basel, 30 January 2019 Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer’s disease (AD) – other company programmes in AD continue The Alzheimer’s Prevention Initiative (API) study of crenezumab in familial Alzheimer’s disease continues Roche remains committed to ongoing clinical studies in Alzheimer’s disease, including GRADUATE Phase... Read more

January 17, 2019 Acad, Gov/Utilities

FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer

Basel, 17 January 2019 FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for... Read more

January 14, 2019 Bio/Pharma/CRO M&A, Partnerships

Merck and Roche Renew Global Distribution Agreement

DISTRIBUTION AGREEMENT ANNOUNCEMENT January 14, 2019 Merck and Roche Renew Global Distribution Agreement Global distribution agreement renewed under existing terms for additional five years Includes Biochemical Reagents and Kapa Biosystems portfolios, and select qPCR & Nucleic Acid Purification products Merck and Roche have agreed to renew their current distribution agreement for the Biochemical Reagents and... Read more

January 9, 2019 Clinical Research/Diagn. Product Launch

Roche launches new cobas pro integrated solutions to significantly reduce manual operations in labs

cobas pro integrated solutions enhances automated procedures to overcome key challenges in lab management This new Serum Work Area solution in the cobas family minimizes hands-on time and maximizes productivity through automated procedures This new innovation offers flexibility for future changing testing needs, enabling labs to further deliver quality patient care  Basel, 9 Jan. 2019 Roche (SIX: RO,... Read more

December 17, 2018 Acad, Gov/Utilities Licensing, IP, and Legal

PRIME designation granted by European Medicines Agency for Roche’s risdiplam for treatment of spinal muscular atrophy (SMA)

Basel, 17 December 2018 PRIME designation granted by European Medicines Agency for Roche’s risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the treatment of SMA Types 1, 2 and 3; a rare and debilitating genetic disease most commonly diagnosed in children European Medicines Agency PRIME... Read more

December 10, 2018 PR/Corporate

New member proposed for election to Roche Board of Directors

Basel, 10 December 2018 New member proposed for election to Roche Board of Directors Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that at its December meeting the Board of Directors (BoD) of Roche Holding Ltd decided on first proposals for approval by the Annual General Meeting (AGM), scheduled for 5 March 2019. The BoD... Read more

December 10, 2018 PR/Corporate

Changes to the Roche Corporate Executive Committee

Basel, 10 December 2018 Changes to the Roche Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Daniel O’Day, CEO Roche Pharmaceuticals and member of the Corporate Executive Committee, will be stepping down from his role as of 31 December 2018. Until the end of February 2019 and prior to assuming new... Read more

December 7, 2018 Acad, Gov/Utilities

FDA approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer

Basel, 07 December 2018 FDA approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer Approval based on survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no... Read more

December 5, 2018 Uncategorized

Roche’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment

Basel, 05 December 2018 Roche’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared... Read more

December 5, 2018 Acad, Gov/Utilities

FDA grants priority review to Roche’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer

Basel, 05 December 2018 FDA grants priority review to Roche’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for... Read more